Recombinant erythropoietin biosimilar - North China Pharmaceutical Corporation

Drug Profile

Recombinant erythropoietin biosimilar - North China Pharmaceutical Corporation

Alternative Names: GerEPO; rhEPO - North China Pharmaceutical Corporation

Latest Information Update: 26 Sep 2014

Price : $50

At a glance

  • Originator North China Pharmaceutical Corporation
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 26 Sep 2014 Launched prior to this date for Anaemia in China (SC)
  • 26 Sep 2014 Launched prior to this date for Anaemia in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top